SBC Medical Group Holdings Incorporated (Nasdaq: SBC) announced its financial results for the fourth quarter and full year of 2025, revealing a notable improvement in profitability despite a decline in total revenues. For the fourth quarter, total revenues were reported at $40 million, reflecting an 11% decrease year-over-year. However, net income attributable to the company surged to $14 million, marking a remarkable 117% increase compared to the previous year. Earnings per share (EPS) for the quarter reached $0.14, more than doubling from the prior year’s figure of $0.06, indicating a strong recovery in profitability.

The full year results also showed a mixed performance, with total revenues amounting to $174 million, down 15% from 2024. Despite this decline, net income attributable to SBC Medical Group increased by 9% to $51 million, with EPS rising to $0.50 from $0.48. The company’s EBITDA for the year was reported at $70 million, representing a 21% decrease, but the EBITDA margin remained robust at 40%.

Chairman and CEO Yoshiyuki Aikawa commented on the results, stating, "Our full-year 2025 results reflect a business in transition. Revenue declined primarily due to structural changes and revisions in franchise fee arrangements. However, our underlying profitability strengthened considerably, with net income margin expanding from 23% to 29%." Aikawa emphasized the company’s focus on advancing its multi-brand strategy and expanding its healthcare portfolio as it moves into 2026.

The company also announced a conference call scheduled for March 27, 2026, to discuss the financial results and provide further insights into its strategic direction. Investors are encouraged to monitor the company’s website for updates and additional information.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.